Prices delayed by at least 15 minutes | Print


Champions Oncology (CSBR)

Common Shares
Sell: $5.03|Buy: $5.34|Change: 0.04 (-0.79%)

Open 

$5.03


Previous close 

$5.07


Trade high 

$5.03


Volume 

1,377


Year high 

$7.32


Year low 

$4.17


Dividend yield 

-


Market capitalisation 

$68.38 mn


P/E ratio 

416.67


ISIN 

US15870P3073


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 24/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Champions Oncology- 0.79
More...

Company profile

Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.